The 2026 cycle is live. Two things changed this time.
First, the index is now 20 companies rather than the wider list we ran previously. We would rather publish deeper evidence on fewer companies than thin evidence on many.
Second, there is a new company at the top. Sovrn Research scored 98, the highest Index Score we have issued, and led all six weighted dimensions rather than winning on one or two. American Peptides placed second at 94 and Oath Research third at 92.
Specimen-level reports for the three new entries are being prepared and will appear on their profiles. Until they are up, treat those scores as our summary rather than as something you can independently check. That is the standard we hold every company to, so it is fair to hold us to it as well.
Methodology is unchanged from v3.0 and is published in full. If you think the weighting is wrong, that thread is open.
EV EvidenceFirst Mod · · 34 found helpful
Appreciate the note about the specimen reports not being up yet. Would have been easy to just publish the score and hope nobody asked.